Table 1. Baseline patient characteristics.
| Variable | N (%) |
|---|---|
| Age (years), median (range) | 63 (37–82) |
| Male gender | 17 (71.8) |
| Pathology | |
| Adenocarcinoma | 15 (62.5) |
| Squamous cell carcinoma | 9 (37.5) |
| Stage | |
| III | 4 (16.7) |
| IV | 20 (83.3) |
| ECOG | |
| 0 | 1 (4.2) |
| 1 | 15 (62.5) |
| 2 | 8 (33.3) |
| Smoking History | |
| Never | 11 (45.8) |
| Former | 2 (8.4) |
| Always | 11 (45.8) |
| LIPI | |
| 0 | 14 (58.3) |
| 1 | 8 (33.3) |
| 2 | 2 (8.4) |
| PD-L1 | |
| Positive (≥1%) | 13 (54.1) |
| Negative (<1%) | 10 (41.7) |
| Unknown | 1 (4.2) |
| EGFR | |
| Mutant | 3 (12.5) |
| Wildtype | 17 (70.8) |
| Unknown | 4 (16.7) |
| ALK | |
| Wildtype | 20 (83.3) |
| Unknown | 4 (16.7) |
| KRAS | |
| Mutant | 4 (16.7) |
| Wildtype | 13 (54.1) |
| Unknown | 7 (29.2) |
| TP53 | |
| Mutant | 5 (20.8) |
| Wildtype | 10 (41.7) |
| Unknown | 9 (37.5) |
ECOG, performance score of Eastern Cooperative Oncology Group; LIPI, the lung immune prognostic index.